This program will include a discussion of offlabel treatment not approved by the FDA for use in the United States Introduction Use of Neuromuscular Blocking Agent I mproves I ntubation C ID: 650883
Download Presentation The PPT/PDF document "Residual Paralysis Is More Common Than Y..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Residual Paralysis Is More Common Than You ThinkSlide2
This program will include a discussion of off-label treatment not approved by the FDA for use in the United States. Slide3
IntroductionSlide4
Use of Neuromuscular Blocking Agent I
mproves
I
ntubation
C
onditionsSlide5
Improved Tracheal Intubation Conditions Associated
With Less Laryngeal Complications Postsurgery Slide6
Achieving Optimal Surgical ConditionsSlide7
Deep NMB vs No NMBSlide8
Dose-Dependent Relationship Between NMBAs and Postoperative Respiratory ComplicationsSlide9
NMBAs and Hospital ReadmissionSlide10
NMBAs and Residual ParalysisSlide11
Residual NMBSlide12
Risk Factors Associated With Postoperative Pulmonary ComplicationsSlide13
Strategies to Prevent, Reduce, and Manage Residual ParalysisSlide14
Does Quantitative Monitoring Lead to Decreased Risk of AEs?Slide15
Quantitative Monitoring Reduces Incidence of Respiratory AEsSlide16
Proper Monitoring: Qualitative vs QuantitativeSlide17
NeostigmineSlide18
Neostigmine (cont)Slide19
MGH Dept. of Anesthesia and Critical Care Pain Medicine Quality Improvement ProjectSlide20
MGH DACCPM Cognitive AidSlide21
Results of MGH DACCPM Quality Improvement ProjectSlide22
SugammadexSlide23
Sugammadex (cont)Slide24
How Much Sugammadex?Slide25
Contraindications for SugammadexSlide26
Concluding RemarksSlide27
AbbreviationsSlide28
Abbreviations (cont)